Literature DB >> 2554607

Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents.

M Ertürk1, M J Welch, R J Phillpotts, R Jennings.   

Abstract

Guinea-pigs immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation responded with EIA and NT serum antibody titres that were significantly greater than those elicited by a non-ionic detergent-extracted antigen preparation inoculated using a similar dosage schedule. Following intravaginal challenge of the guinea-pigs with HSV-2 (strain SH/B), there was no statistically significant difference in the protection afforded to these animals by the two antigen preparations, although the results indicated the zwitterionic detergent-extracted HSV-1 antigen preparation to be slightly superior in this respect. In mice, the zwitterionic detergent-extracted HSV-1 antigen preparation elicited an EIA antibody response and partial protection against homologous virus challenge. The relevance of these animal models to determination of immunogenicity and efficacy of HSV vaccines prepared for use in man, and the reasons for the differences in immunogenicity of these HSV-1 antigen preparations in guinea-pigs, are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554607     DOI: 10.1016/0264-410x(89)90158-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.

Authors:  M Erturk; T J Hill; C Shimeld; R Jennings
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.

Authors:  A al-Ghamdi; R Jennings; H Bentley; C W Potter
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

3.  Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.

Authors:  Richard Brans; Natali V Akhrameyeva; Feng Yao
Journal:  J Invest Dermatol       Date:  2009-04-09       Impact factor: 8.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.